SMALL MOLECULE INHIBITORS OF STAT3: A COMPARATIVE ANALYSIS BY CELL BASED ASSAYS AND MOLECULAR DYNAMICS SIMULATIONS

Autor: Brambilla, L., Laurini, Erik, Genini, D., Jovic, S., Pricl, Sabrina, Catapano, C. V.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::f614edeb75289086394055c9bbd74ade
https://hdl.handle.net/11368/2561131

STAT3: Key targets of growth-promoting receptor positive breast cancer.

Autor: Jiang, Rui-yuan^1,2 (AUTHOR), Zhu, Jia-yu^1,2 (AUTHOR), Zhang, Huan-ping^2,3 (AUTHOR), Yu, Yuan² (AUTHOR), Dong, Zhi-xin⁴ (AUTHOR), Zhou, Huan-huan^1,2 (AUTHOR) zhhuan77@163.com, Wang, Xiaojia² (AUTHOR) wxiaojia0803@163.com

Publikováno v: Cancer Cell International. 10/28/2024, Vol. 24 Issue 1, p1-41. 41p.

The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents.

Autor: Spriano F; Università della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland., Chung EYL; Università della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland., Gaudio E; Università della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland., Tarantelli C; Università della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland., Cascione L; Università della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland.; Swiss Institute of Bioinformatics, Lausanne, Switzerland., Napoli S; Università della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland., Jessen K; Oncternal Therapeutics, San Diego, California., Carrassa L; Department of Oncology, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy., Priebe V; Università della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland., Sartori G; Università della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland., Graham G; Departments of Oncology and Pediatrics, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC., Selvanathan SP; Departments of Oncology and Pediatrics, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC., Cavalli A; Università della Svizzera italiana, Institute of Biomedical Research, Bellinzona, Switzerland., Rinaldi A; Università della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland., Kwee I; Università della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland.; Swiss Institute of Bioinformatics, Lausanne, Switzerland.; Dalle Molle Institute for Artificial Intelligence, Manno, Switzerland., Testoni M; Università della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland., Genini D; Università della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland., Ye BH; Department of Cell Biology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, New York., Zucca E; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland., Stathis A; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland., Lannutti B; Oncternal Therapeutics, San Diego, California., Toretsky JA; Departments of Oncology and Pediatrics, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC., Bertoni F; Università della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland. frbertoni@mac.com.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2019 Aug 15; Vol. 25 (16), pp. 5167-5176. Date of Electronic Publication: 2019 Jun 10.

Mitochondrial dysfunction induced by a SH2 domain-targeting STAT3 inhibitor leads to metabolic synthetic lethality in cancer cells.

Autor: Genini D; Tumor Biology and Experimental Therapeutics Program, Institute of Oncology Research, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland., Brambilla L; Tumor Biology and Experimental Therapeutics Program, Institute of Oncology Research, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland.; Molecular Oncology and Immunology Program, New York University School of Medicine, New York, NY 10016., Laurini E; Molecular Simulation Engineering Laboratory, University of Trieste, 34127 Trieste, Italy., Merulla J; Tumor Biology and Experimental Therapeutics Program, Institute of Oncology Research, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland., Civenni G; Tumor Biology and Experimental Therapeutics Program, Institute of Oncology Research, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland., Pandit S; Tumor Biology and Experimental Therapeutics Program, Institute of Oncology Research, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland., D'Antuono R; Institute for Research in Biomedicine, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland., Perez L; Institute for Research in Biomedicine, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland., Levy DE; Molecular Oncology and Immunology Program, New York University School of Medicine, New York, NY 10016., Pricl S; Molecular Simulation Engineering Laboratory, University of Trieste, 34127 Trieste, Italy., Carbone GM; Tumor Biology and Experimental Therapeutics Program, Institute of Oncology Research, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland., Catapano CV; Tumor Biology and Experimental Therapeutics Program, Institute of Oncology Research, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland; carlo.catapano@ior.iosi.ch.; Department of Oncology, Faculty of Biology and Medicine, University of Lausanne, 1015 Lausanne, Switzerland.

Publikováno v: Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2017 Jun 20; Vol. 114 (25), pp. E4924-E4933. Date of Electronic Publication: 2017 Jun 05.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.